FOXP1 and diffuse large B-cell lymphoma: Bamham et al. showed that in patients with diffuse large B-cell lymphoma (DLBCL) the transcription factor FOXP1-positive group had a significant decreased overall survival in comparison with the FOXP1-negative group (P = 0.0001) [12].